Drostanolone Enanthate
The long-ester version of drostanolone (Masteron), pharmacologically identical to the propionate but with a slower release allowing less frequent injection. It shares the same DHT-derived, non-aromatising, dry-hardening profile and the same androgenic side-effect pattern; only the ester and dosing frequency differ. Human clinical data are limited to the older propionate breast-cancer use.
01 Overview
Drostanolone enanthate delivers the identical active steroid as drostanolone propionate, attached to a longer enanthate ester that extends the half-life and lets users inject roughly twice weekly instead of every other day. The active-compound pharmacology — 2-alpha-methyl-DHT, non-aromatising, mildly anti-oestrogenic, cosmetically 'hardening' — is unchanged.
There is no separate clinical literature for the enanthate ester; its evidence base is that of drostanolone generally, so the research score reflects thin, largely dated and anecdotal human data. Because the ester is longer, steady-state takes longer to reach and the compound clears more slowly, mildly lengthening the detection window relative to the propionate.
02 Mechanism
Identical to drostanolone propionate — a DHT-derived androgen-receptor agonist that cannot aromatise — differing only in the enanthate ester's slower release and longer half-life.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Common | 300–500 mg/wk | IM | Injected roughly twice weekly. |
| Heavy | 500–600 mg/wk | IM | Best results at low body fat. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Hardening / dry, defined lookSame cosmetic hardening as propionate; anecdotal, most visible when lean. | Anecdotal | ||
| Mild anti-oestrogenic effectInherited from drostanolone's documented anti-oestrogenic action. | Clinical | ||
| Less frequent injectionLonger ester reduces injection frequency versus propionate. | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Acne and oily skinAndrogenic sebaceous stimulation. | Mild | Common | Observational | |
| Accelerated male-pattern hair lossPotent DHT derivative hastens scalp hair loss in the predisposed. | Moderate | Common | Observational | |
| HPTA suppressionSuppresses endogenous testosterone. | Severe | Universal | Observational |
06 Commonly used with
What drostanolone is combined with, and why. This is about intent rather than safety — the interactions table below covers what is dangerous. Nothing here is listed without what it costs.
| Compound | Frequency | Purpose & trade-off |
|---|---|---|
| Stacked compounds | ||
| Testosteroneenanthate base | Long-ester Masteron is paired ester-for-ester with testosterone enanthate as the anabolic base, keeping injection schedules aligned across a longer cycle.Trade-off: The long half-life means androgenic sides and blood-level swings resolve slowly if problems arise, and the testosterone base still aromatises. | |
| Boldenone undecylenateEQ, lean bulk | Combined in longer lean-mass cycles where EQ drives slow quality gains and appetite while enanthate-Masteron adds hardening and mild anti-estrogenic support.Trade-off: Both are long esters that take weeks to clear, EQ can raise haematocrit and anxiety, and the combined androgen load still promotes hair and skin sides. | |
| Support & ancillaries | ||
| AnastrozoleAI | Manages aromatisation from the testosterone base across the long cycle so estrogen-driven water retention does not undermine the hardening goal.Trade-off: AI dosing must be titrated carefully over weeks; crashing estradiol harms lipids, joints and mood, effects that linger with long esters on board. | |
| Post-cycle | ||
| ClomifenePCT | Started after the long esters clear to stimulate LH and FSH and recover endogenous testosterone suppressed by the cycle.Trade-off: Recovery is not guaranteed, and clomifene frequently causes mood swings and visual side effects that can be more pronounced than with tamoxifen. | |